MYC, Metabolic Synthetic Lethality, and Cancer

doi:10.1007/978-3-319-42118-6_4

Review

. 2016:207:73-91.

doi: 10.1007/978-3-319-42118-6_4.

MYC, Metabolic Synthetic Lethality, and Cancer

Annie L Hsieh^{1

2

3}, Chi V Dang^{4

5

6}

Affiliations

¹ Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁴ Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. dangvchi@exchange.upenn.edu.
⁵ Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. dangvchi@exchange.upenn.edu.
⁶ Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. dangvchi@exchange.upenn.edu.

PMID: 27557535
DOI: 10.1007/978-3-319-42118-6_4

Review

MYC, Metabolic Synthetic Lethality, and Cancer

Annie L Hsieh et al. Recent Results Cancer Res. 2016.

. 2016:207:73-91.

doi: 10.1007/978-3-319-42118-6_4.

Authors

Annie L Hsieh^{1

2

3}, Chi V Dang^{4

5

6}

Affiliations

¹ Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
² Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
⁴ Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. dangvchi@exchange.upenn.edu.
⁵ Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. dangvchi@exchange.upenn.edu.
⁶ Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. dangvchi@exchange.upenn.edu.

PMID: 27557535
DOI: 10.1007/978-3-319-42118-6_4

Abstract

The MYC oncogene plays a pivotal role in the development and progression of human cancers. It encodes a transcription factor that has broad reaching effects on many cellular functions, most importantly in driving cell growth through regulation of genes involved in ribosome biogenesis, metabolism, and cell cycle. Upon binding DNA with its partner MAX, MYC recruits factors that release paused RNA polymerases to drive transcription and amplify gene expression. At physiologic levels of MYC, occupancy of high-affinity DNA-binding sites drives 'house-keeping' metabolic genes and those involved in ribosome and mitochondrial biogenesis for biomass accumulation. At high oncogenic levels of MYC, invasion of low-affinity sites and enhancer sequences alter the transcriptome and cause metabolic imbalances, which activates stress response and checkpoints such as p53. Loss of checkpoints unleashes MYC's full oncogenic potential to couple metabolism with neoplastic cell growth and division. Cells that overexpress MYC, however, are vulnerable to metabolic perturbations that provide potential new avenues for cancer therapy.

Keywords: Cancer therapy; Glucose; Glutamine; MYC oncogene; Metabolism; Ribosome biogenesis.

PubMed Disclaimer

Cited by

The SUMO pathway in pancreatic cancer: insights and inhibition.
Schneeweis C, Hassan Z, Schick M, Keller U, Schneider G. Schneeweis C, et al. Br J Cancer. 2021 Feb;124(3):531-538. doi: 10.1038/s41416-020-01119-6. Epub 2020 Oct 19. Br J Cancer. 2021. PMID: 33071285 Free PMC article. Review.
Myc as a Regulator of Ribosome Biogenesis and Cell Competition: A Link to Cancer.
Destefanis F, Manara V, Bellosta P. Destefanis F, et al. Int J Mol Sci. 2020 Jun 5;21(11):4037. doi: 10.3390/ijms21114037. Int J Mol Sci. 2020. PMID: 32516899 Free PMC article. Review.
Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma.
Liu X, Song X, Zhang J, Xu Z, Che L, Qiao Y, Ortiz Pedraza Y, Cigliano A, Pascale RM, Calvisi DF, Liu Y, Chen X. Liu X, et al. Cancer Med. 2018 Dec;7(12):6170-6181. doi: 10.1002/cam4.1777. Epub 2018 Oct 28. Cancer Med. 2018. PMID: 30370649 Free PMC article.
Protein synthesis inhibitors stimulate MondoA transcriptional activity by driving an accumulation of glucose 6-phosphate.
Wilde BR, Kaadige MR, Guillen KP, Butterfield A, Welm BE, Ayer DE. Wilde BR, et al. Cancer Metab. 2020 Dec 4;8(1):27. doi: 10.1186/s40170-020-00233-6. Cancer Metab. 2020. PMID: 33292639 Free PMC article.
R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m⁶A/PFKP/LDHB axis.
Qing Y, Dong L, Gao L, Li C, Li Y, Han L, Prince E, Tan B, Deng X, Wetzel C, Shen C, Gao M, Chen Z, Li W, Zhang B, Braas D, Ten Hoeve J, Sanchez GJ, Chen H, Chan LN, Chen CW, Ann D, Jiang L, Müschen M, Marcucci G, Plas DR, Li Z, Su R, Chen J. Qing Y, et al. Mol Cell. 2021 Mar 4;81(5):922-939.e9. doi: 10.1016/j.molcel.2020.12.026. Mol Cell. 2021. PMID: 33434505 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

MYC, Metabolic Synthetic Lethality, and Cancer

Affiliations

MYC, Metabolic Synthetic Lethality, and Cancer

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Other Literature Sources

Research Materials

Miscellaneous

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Other Literature Sources

Research Materials

Miscellaneous